Leap Therapeutics Inc Total Liabilities

Latest as of September 2025: $8.70 Million USD

Leap Therapeutics Inc total liabilities. Based on the latest financial reports, Leap Therapeutics Inc (LPTX) has total liabilities worth $8.70 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Leap Therapeutics Inc's assets to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Leap Therapeutics Inc (2012–2024)

Total liabilities of Leap Therapeutics Inc from 2012 to 2024. This chart illustrates how Leap Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.

Leap Therapeutics Inc Competitors by Total Liabilities

The table below lists competitors of Leap Therapeutics Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Gabelli Global Utility & Income Tr NYSE MKT:GLU	USA	$291.78K
Dohwa Engin KO:002150	Korea	₩473.43 Billion
INNATE PHARMA SP.ADR/1 F:IDDA	Germany	€84.42 Million
Chongkundang KO:001630	Korea	₩814.73 Billion
Winchester Bancorp, Inc. Common Stock NASDAQ:WSBK	USA	$975.42 Million
Epileds Technologies Inc TW:4956	Taiwan	NT$1.09 Billion
Arcticzymes Technologies ASA OL:AZT	Norway	Nkr32.25 Million
American Resources Corp Class A NASDAQ:AREC	USA	$75.72 Million

Liability Composition Analysis (2012–2024)

This chart breaks down Leap Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Leap Therapeutics Inc's balance sheet.

Liquidity & Leverage Metrics

Leap Therapeutics Inc Total Liabilities Ratios Explained

Leap Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	1.21	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	3.23	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.76	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Leap Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Leap Therapeutics Inc (2012–2024)

The table below shows the annual total liabilities of Leap Therapeutics Inc from 2012 to 2024.

Year	Total Liabilities	Change
2024-12-31	$14.08 Million	+10.97%
2023-12-31	$12.68 Million	+267.76%
2022-12-31	$3.45 Million	-65.59%
2021-12-31	$10.02 Million	+233.02%
2020-12-31	$3.01 Million	-67.27%
2019-12-31	$9.20 Million	-7.09%
2018-12-31	$9.90 Million	-44.84%
2017-12-31	$17.95 Million	+177.92%
2016-12-31	$6.46 Million	+404.85%
2015-12-31	$1.28 Million	-48.59%
2014-12-31	$2.49 Million	+26.23%
2013-12-31	$1.97 Million	-57.27%
2012-12-31	$4.61 Million	--

About Leap Therapeutics Inc

NASDAQ:LPTX USA Biotechnology

Market Cap

$116.14 Million

Market Cap Rank

#18430 Global

#4306 in USA

Share Price

$2.05

Change (1 day)

+368.57%

52-Week Range

$0.41 - $2.05

All Time High

$100.10